The U.S. Senate Judiciary Committee on Monday postponed a hearing planned for next week to discuss Mylan NV's pending $465 million settlement to resolve charges that it underpaid government healthcare programs by misclassifying its EpiPen emergency allergy treatment. Mylan, the Justice Department and the Centers for Medicare and Medicaid Services had all declined to send officials to the Nov. 30 hearing, the committee said in a statement. “Unfortunately, because of the unconventional refusal by these three entities to attend, we must now consider compelling their participation,” committee Chairman Charles Grassley said in the statement.
More here:
U.S. Senate panel postpones Mylan hearing
